Device Medical Device

Igt Devices Undivided

Payments companies reported to CMS as associated with Igt Devices Undivided. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.6Massociated payments (2023-2025)
852clinicians with associated payments
1company reporting

By year

2025 $1.6M

Payments reported as associated with Igt Devices Undivided, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Interventional Cardiology $426K
Cardiovascular Disease $401K
Clinical Cardiac Electrophysiology $249K
Vascular Surgery $151K
Thoracic Surgery (Cardiothoracic Vascular Surgery) $82K
Vascular & Interventional Radiology $81K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Igt Devices Undivided

These are the largest totals companies reported as associated with Igt Devices Undivided. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Christopher Healy Indianapolis, IN Cardiovascular Disease $70,731.83
Karim Al-Azizi Plano, TX Interventional Cardiology $67,705.00
Rogerio Carrillo Hialeah, FL Thoracic Surgery (Cardiothoracic Vascular Surgery) $65,518.17
Edris Aman Sacramento, CA Cardiovascular Disease $57,974.45
Erin Murphy Charlotte, NC Vascular Surgery $57,836.38
Thomas Callahan Cleveland, OH Clinical Cardiac Electrophysiology $48,326.15
Jasvindar Singh Saint Louis, MO Interventional Cardiology $37,081.05
Micah Watts Galloway, NJ Vascular & Interventional Radiology $35,213.06
Gagan Singh Sacramento, CA Cardiovascular Disease $28,861.37
Robert Lewis Birmingham, AL Internal Medicine $28,515.68

Prescribed Igt Devices Undivided?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.